1202057-39-3

Basic information

• Product Name: (R)-3-(1-AMinoethyl)aniline dihydrochloride
• Synonyms: (R)-3-(1-AMinoethyl)aniline dihydrochloride;(R)-3-(1-AMinoethyl)aniline;3-[(1R)-1-aminoethyl]aniline,dihydrochloride;(R)-3-AMINO-ALPHA-METHYL-BENZENEMETHANAMINE-2HCl;(R)-3-Amino-α-methylbenzylamine
• CAS NO: 1202057-39-3
• Molecular Formula: C8H12N2
• Molecular Weight: 136.19428
• Mol File: 1202057-39-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 266.5±15.0 °C(Predicted)
• Appearance: /
• Density: 1.056±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 9.06±0.10(Predicted)
• CAS DataBase Reference: (R)-3-(1-AMinoethyl)aniline dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-3-(1-AMinoethyl)aniline dihydrochloride(1202057-39-3)
• EPA Substance Registry System: (R)-3-(1-AMinoethyl)aniline dihydrochloride(1202057-39-3)

Safety Data

• Hazardous Substances Data: 1202057-39-3(Hazardous Substances Data)

Usage

General Description

(R)-3-(1-AMinoethyl)aniline dihydrochloride, also known as (R)-(-)-1-(3-Aminophenyl)ethylamine hydrochloride, is a chemical compound that belongs to the class of aliphatic amines. It is a white to off-white crystalline powder that is soluble in water. (R)-3-(1-AMinoethyl)aniline dihydrochloride has a molecular formula of C8H13Cl2N and a molecular weight of 191.10 g/mol. It is commonly used as a reagent in chemical synthesis and pharmaceutical research, particularly in the production of pharmaceutical drugs and organic compounds. Its properties make it suitable for use in various applications in the field of chemistry and medicine.

Upstream product

• 5400-78-2 1-(3-nitrophenyl)ethanol 
• 90271-37-7 3-nitro-α-methylbenzylamine 
• 246240-16-4 1-(1-azidoethyl)-3-nitrobenzene 
• 121-89-1 3-Nitroacetophenone 
• 90271-37-7 (S)-1-(3 -nitrophenyl)ethan-1-amine 
• 7471-32-1 m-nitroacetophenone oxime 
• 6011-18-3 1-(3-aminophenyl)ethanone oxime 

Downstream Products

• 878803-71-5 2-{[(1S)-1-(3-aminophenyl)ethyl]amino}-4-[8-(difluoromethyl)imidazo[1,2-a]pyridin-3-yl]pyrimidine-5-carbonitrile 
• 1610766-86-3 C₂₃H₂₆N₄O₅ 
• 1610766-87-4 C₂₂H₂₄N₄O₅ 
• 1610766-88-5 C₂₃H₂₆N₆O₃ 
• 1610766-95-4 C₂₃H₂₅N₅O₃S 
• 1610766-96-5 C₂₃H₂₈N₄O₄S 
• 1610766-89-6 C₂₄H₂₆N₆O₄ 
• 1610766-90-9 C₂₇H₃₀N₄O₅ 
• 1610766-91-0 C₂₄H₂₈N₄O₄ 
• 1610766-92-1 C₂₄H₂₆N₆O₄ 
• 1610766-93-2 C₂₅H₂₆N₄O₅ 
• 1610766-94-3 C₂₄H₂₄N₄O₅ 
• 1610766-97-6 (2R)-1-cyanobutan-2-yl[(1S)-1-{3-[N'-(4-cyano-3-methoxyphenyl)carbamimidamino]phenyl}ethyl] carbamate 
• 1610766-98-7 C₂₃H₂₉N₅O₄ 

Relevant articles and documents

Design, synthesis and biological evaluation of novel inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitors

This study is based on our attempts to further explore the structure-activity relationship (SAR) of VX-148 (3) in an attempt to identify inosine 5′-mono-phosphate dehydrogenase (IMPDH) inhibitors superior to mycophenolic acid. A five-point pharmacophore developed using structurally diverse, known IMPDH inhibitors guided further design of novel analogs of 3. Several conventional as well as novel medicinal chemistry strategies were tried. The combined structure- and ligand-based approaches culminated in a few analogs with either retained or slightly higher potency. The compounds which retained the potency were also checked for their ability to inhibit human peripheral blood mononuclear cells proliferation. This study illuminates the stringent structural requirements and strict SAR for IMPDH II inhibition.

Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2)

A novel series of inhibitors for mitogen activated protein kinase-activated protein kinase 2 (MK-2) are reported. These squarate based inhibitors were identified via a high-throughput screen. An MK2 co-structure with the starting ligand was obtained and a structure based approach was followed to optimize potency and selectivity.

INHIBITORS OF KINASE ACTIVITY

The present invention relates to pyridines or pyrazines that inhibit kinases. In particular the compounds of the invention inhibit members of the class III PTK receptor family such as FMS (CSF-IR), c-KIT, PDGFRβ, PDGFRα or FLT3 and KDR, SRC, EphA2, EphA3, EphA8, FLTl, FLT4, HCK, LCK, PTK5 (FRK), SYK, DDRl and DDR2 and RET. The compounds of the invention are useful in the treatment of kinase associated diseases such as immunological and inflammatory diseases; hyperproliferative diseases including cancer and diseases involving neo-angiogenesis; renal and kidney diseases; bone remodeling diseases; metabolic diseases; and vascular diseases.